The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Open accessAbstract
BACKGROUND: Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. METHODS: In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring. RESULTS: A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (±SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 61±17% at baseline to 71±12% during the 6 months and remained unchanged at 59±14% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P<0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P = 0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group. CONCLUSIONS: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The largest trial with this class in T1D was with liraglutide, which showed a reduction of A1C of 0.4% with the highest 1.8 mg dose in addition to a 5 kg weight loss and insulin dose reductions.1177”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the introduction of CGM devices that alarm with low blood glucose concentrations and semiautomated pumps that suspend insulin infusion as glucose concentrations decrease have facilitated achieving target HbA 1c levels with less risk for hypoglycemia (332).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hybrid closedloop systems are the most effective means of maintaining glucose in the normal range in people with type 1 diabetes (90,91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of insulin analog regimens are associated with less hypoglycemia, while hybrid closed-loop systems result in both improvement in TIR and reduction in TBR (91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These prestigious publications reported pivotal trials of the commercial descendant of DiAs-a new AID system (Control-IQ by Tandem Diabetes Care)-in different age groups: 14 years old and older, 132 6 to 13 years old, 133 and 2 to 6 years old.134”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“This large-scale study and its continuation with young children ages 2 to 6 years old completed several clinical protocols, three of which were published in the New England Journal of Medicine.[132][133][134]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, glucose time in range (70 -180 mg/dl [3.9 -10.0 mmol/l]) and time in hypoglycemia ( < 70 mg/dl [3.9 mmol/l] and < 54 mg/dl [3.0 mmol/l]) have been used as outcomes for clinical trials 259,260 and have been endorsed as appropriate metrics for clinical care. 229”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that an AID hybrid closed-loop system is superior to AID sensor-augmented pump therapy for increased percentage of time in range and reduction of hypoglycemia (34,35).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“HbA 1c , TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90,91).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although this agent was more effective with those participants still producing endogenous insulin, the added hypoglycemia and ketosis noted has resulted in no attempt for FDA approval in T1D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Experimental — accuracy not yet measuredIn the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Kleinman, L. C., & Norton, E. C. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00900.x · Cited by 287
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 999
Nanomedicine-Based Strategies for Diabetes: Diagnostics, Monitoring, and Treatment
Lemmerman, L. R., Das, D., Higuita‐Castro, N., Mirmira, R. G., & Gallego‐Perez, D. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.02.001 · Cited by 83
Wolkowicz, K. L., Aiello, E. M., Vargas, E., Teymourian, H., Tehrani, F., Wang, J., Pinsker, J. E., Doyle, F. J., Patti, M., Laffel, L. M., et al. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10201 · Cited by 84
Self-citationForlenza, G. P., Buckingham, B. A., Brown, S. A., Bode, B. W., Levy, C. J., Criego, A. B., Wadwa, R. P., Cobry, E. C., Slover, R., Messer, L. H., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0546 · Cited by 79
Self-citationBisio, A., Gonder-Frederick, L. A., McFadden, R. K., Cherñavvsky, D. R., Voelmle, M. K., Pajewski, M., Yu, P. L., Bonner, H., & Brown, S. A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820986879 · Cited by 77
Self-citationDigital twins and artificial intelligence in metabolic disease research
MOSQUERA-LOPEZ, C. M., & Jacobs, P. G. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.019 · Cited by 77
Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
Messer, L. H., Berget, C., Pyle, L. L., Vigers, T., Cobry, E. C., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0165 · Cited by 76
Self-citationJiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 81
Cobry, E. C., Kanapka, L. G., Cengiz, E., CARRIA, L. R., Ekhlaspour, L., Buckingham, B. A., Hood, K. K., Hsu, L. J., Messer, L. H., Schoelwer, M. J., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0532 · Cited by 73
Self-citationForlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., Umpierrez, G., & Aleppo, G. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0206 · Cited by 70
Self-citationSmart-watch-programmed green-light-operated percutaneous control of therapeutic transgenes
Mansouri, M., Hussherr, M., Strittmatter, T., Buchmann, P., Xue, S., Camenisch, G., & Fussenegger, M. (2021) · Nature Communications · doi:10.1038/s41467-021-23572-4 · Cited by 71
Davis, G. M., Peters, A. L., Bode, B. W., Carlson, A. L., Dumais, B., Vienneau, T. E., Huyett, L. M., & Ly, T. T. (2023) · Diabetes Care · doi:10.2337/dc22-1915 · Cited by 69
Kudva, Y. C., Laffel, L. M., Brown, S. A., Raghinaru, D., Pinsker, J. E., Ekhlaspour, L., Levy, C. J., Messer, L. H., Kovatchev, B. P., Lum, J. W., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0089 · Cited by 68
Self-citationRecent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Yu, J. S., Lee, S.-H., & Kim, M. K. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.105 · Cited by 74
Pasqua, M.-R., Tsoukas, M. A., Kobayati, A., Aboznadah, W., Jafar, A., & Haidar, A. (2025) · Nature Medicine · doi:10.1038/s41591-024-03463-z · Cited by 68
Wu, Z.-K., Luo, S.-H., Zheng, X.-Y., Bi, Y., Xu, W., Yan, J.-H., Yang, D.-Z., & Weng, J. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820950146 · Cited by 57
Forlenza, G. P., Ekhlaspour, L., DiMeglio, L. A., Fox, L. A., Rodriguez, H., Shulman, D. I., Kaiserman, K. B., Liljenquist, D. R., Shin, J., Lee, S. W., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13312 · Cited by 66
Self-citationCurrent Status and Emerging Options for Automated Insulin Delivery Systems
Forlenza, G. P., & Lal, R. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0514 · Cited by 70
Self-citationGodoi, A., Marques, I. R., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Júnior, J. E. R. L., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01144-4 · Cited by 79
Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom
Lennerz, B. S., Koutnik, A. P., Azova, S., Wolfsdorf, J. I., & Ludwig, D. S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142246 · Cited by 78
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 66
Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer, M. J., Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cobry, E. C., Messer, L. H., Cengiz, E., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0646 · Cited by 64
Self-citationRandomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1310 · Cited by 60
Self-citationSemaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
Boscari, F., & Avogaro, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09635-3 · Cited by 70
Biester, T., Muller, I., Berge, T. V. D., Atlas, E., Nimri, R., Phillip, M., Battelino, T., Bratina, N., Dovč, K., Scheerer, M. F., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14258 · Cited by 61
Golledge, J., Fernando, M. E., Lazzarini, P. A., Najafi, B., & Armstrong, D. G. (2020) · Sensors · doi:10.3390/s20164527 · Cited by 65
Fabris, C., Heinemann, L., Beck, R., Cobelli, C., & Kovatchev, B. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0236 · Cited by 58
Self-citationDigital Technology for Diabetes
Hughes, M. S., Addala, A., & Buckingham, B. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2215899 · Cited by 59
Self-citationInfante, M., Baidal, D. A., Rickels, M. R., Fabbri, A., Skyler, J. S., Alejandro, R., & Ricordi, C. (2021) · Artificial Organs · doi:10.1111/aor.14023 · Cited by 62
Kariyawasam, D., Morin, C., Casteels, K., Tallec, C. L., Sfez, A., Godot, C., Huneker, E., Garrec, N., Benhamou, P., Polak, M., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00271-5 · Cited by 61
Szmuilowicz, E. D., Levy, C. J., Buschur, E., & Polsky, S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0540 · Cited by 59
Self-citationTsoukas, M. A., Majdpour, D., Yale, J., Fathi, A. E., Garfield, N., Rutkowski, J., René, J., Legault, L., & Haidar, A. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00139-4 · Cited by 65
The role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
Beato-Víbora, P. I., Chico, A. I., Moreno-Fernández, J., Bellido, V., Nattero‐Chávez, L., César, M. J. P., Martínez‐Brocca, M. A., Giménez, M., Aguilera, E., Climent, E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1355 · Cited by 57
Bisio, A., Brown, S. A., McFadden, R. K., Pajewski, M., Yu, P. L., DeBoer, M. D., Schoelwer, M. J., Bonner, H., WAKEMAN, C. A., Cherñavvsky, D. R., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13164 · Cited by 57
Self-citationReal-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations
Bailey, T. S., & Alva, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0236 · Cited by 60
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M. J., Jost, E., CARRIA, L. R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1729 · Cited by 59
Self-citationEkhlaspour, L., Schoelwer, M. J., Forlenza, G. P., DeBoer, M. D., Norlander, L., Hsu, L. J., KINGMAN, R. S., Boranian, E., Berget, C., Emory, E. G., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0507 · Cited by 55
Self-citationGhanim, R. W., Kaushik, A., Park, J., & Abramson, A. (2023) · Device · doi:10.1016/j.device.2023.100092 · Cited by 57
Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial
Brown, S. A., Beck, R. W., Raghinaru, D., Buckingham, B. A., Laffel, L. M., Wadwa, R. P., Kudva, Y. C., Levy, C. J., Pinsker, J. E., Dassau, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0124 · Cited by 55
Self-citationWilson, L. M., Jacobs, P. G., Ramsey, K., Resalat, N., Reddy, R. K. K., Branigan, D. L., LEITSCHUH, J. A., Gabo, V. B., Guillot, F. H., Senf, B., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2267 · Cited by 56
Algorithms for Automated Insulin Delivery: An Overview
Thomas, A., & Heinemann, L. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211008442 · Cited by 60
Karakus, K. E., Akturk, H. K., Alonso, G. T., Snell-Bergeon, J. K., & Shah, V. N. (2023) · Diabetes Care · doi:10.2337/dc23-0495 · Cited by 52
Lee, S., & Yoon, K. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0163 · Cited by 60
Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells
Mansouri, M., & Fussenegger, M. (2021) · Protein & Cell · doi:10.1007/s13238-021-00876-1 · Cited by 52
Renard, É., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., & Kovatchev, B. P. (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 56
Self-citationAhmadi, S. S., Westman, K., Pivodic, A., Ólafsdóttir, A. F., Dahlqvist, S., Hirsch, I. B., Hellman, J., Ekelund, M., Heise, T., Polonsky, W. H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2606 · Cited by 52
Severe Hypoglycemia: Is It Still a Threat for Children and Adolescents With Type 1 Diabetes?
Urakami, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00609 · Cited by 55
Monitoring of Pediatric Type 1 Diabetes
Marks, B. E., & Wolfsdorf, J. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00128 · Cited by 55
Prahalad, P., Zaharieva, D. P., Addala, A., New, C., Scheinker, D., Desai, M., Hood, K. K., & Maahs, D. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00360 · Cited by 57
Fuchs, J., & Hovorka, R. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.679484 · Cited by 51
Garcia-Tirado, J., Diaz, J. L., Esquivel-Zuniga, R., Koravi, C. L. K., Corbett, J. P., Dawson, M., Wakeman, C., Barnett, C. L., Oliveri, M. C., Myers, H., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0932 · Cited by 52
Ekhlaspour, L., Town, M., Raghinaru, D., Lum, J. W., Brown, S. A., & Buckingham, B. A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0524 · Cited by 50
Self-citationKarges, B., Rosenbauer, J., Stahl‐Pehe, A., Flury, M., Biester, T., Tauschmann, M., Lilienthal, E., Hamann, J., Galler, A., & Holl, R. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00284-5 · Cited by 50
Barriers to Uptake of Insulin Technologies and Novel Solutions
PAULEY, M. E., Berget, C., Messer, L. H., & Forlenza, G. P. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s312858 · Cited by 51
Self-citationGraham, R., Müeller, L., Manning, M., HABIF, S., Messer, L. H., Pinsker, J. E., & Aronoff-Spencer, E. S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0341 · Cited by 49
Self-citationEichenlaub, M., Pleus, S., Rothenbühler, M., Bailey, T. S., Bally, L., Brazg, R., Bruttomesso, D., Diem, P., Boija, E. E., Fokkert, M. J., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0465 · Cited by 51
Wireless Battery-free and Fully Implantable Organ Interfaces
Bhatia, A., Hanna, J., Stuart, T., Kasper, K. A., Clausen, D. M., & Gutruf, P. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00425 · Cited by 50
Ng, S. M., Wright, N. P., Yardley, D., Campbell, F., Randell, T. L., Trevelyan, N., Ghatak, A., & Hindmarsh, P. C. (2024) · BMC Medicine · doi:10.1186/s12916-024-03396-x · Cited by 49
Guillot, F. H., Jacobs, P. G., Wilson, L. M., Youssef, J. E., Gabo, V. B., Branigan, D. L., Tyler, N. S., Ramsey, K., Riddell, M. C., & Castle, J. R. (2020) · Biosensors · doi:10.3390/bios10100138 · Cited by 50
Kovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A. (2022) · Diabetes Care · doi:10.2337/dc22-1217 · Cited by 49
Self-citationAutomated Insulin Delivery in Adults With Type 2 Diabetes
Pasquel, F. J., Davis, G. M., Huffman, D. M., Peters, A. L., Parker, J. C., Laffel, L. M., Romeo, G. R., Mathew, J. T., CASTORINO, K. N., Kruger, D. F., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.59348 · Cited by 52
Self-citationKovatchev, B. P., Kollar, L. L., Anderson, S. M., Barnett, C. L., Breton, M. D., Carr, K., Gildersleeve, R., Oliveri, M. C., WAKEMAN, C. A., & Brown, S. A. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30218-3 · Cited by 47
Self-citationQuantifying the impact of physical activity on future glucose trends using machine learning
Tyler, N. S., MOSQUERA-LOPEZ, C. M., Young, G. M., Youssef, J. E., Castle, J. R., & Jacobs, P. G. (2022) · iScience · doi:10.1016/j.isci.2022.103888 · Cited by 49
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
Berget, C., Aktürk, H. K., Messer, L. H., Vigers, T., Pyle, L. L., Snell‐Bergeon, J. K., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14441 · Cited by 46
Self-citationGarcia‐Tirado, J., Brown, S. A., Laichuthai, N., Colmegna, P. H., Koravi, C. L. K., Özaslan, B., Corbett, J. P., Barnett, C. L., Pajewski, M., Oliveri, M. C., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0516 · Cited by 49
Self-citationGarcia‐Tirado, J., Lv, D., Corbett, J. P., Colmegna, P. H., & Breton, M. D. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106401 · Cited by 46
Mansouri, M., Xue, S., Hussherr, M., Strittmatter, T., Camenisch, G., & Fussenegger, M. (2021) · Small · doi:10.1002/smll.202101939 · Cited by 45
Garcia‐Tirado, J., Colmegna, P. H., Villard, O., Diaz, J. L., Esquivel-Zuniga, R., Koravi, C. L. K., Barnett, C. L., Oliveri, M. C., Fuller, M. R., Brown, S. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0119 · Cited by 45
Self-citationvan Bon, A. C., Blauw, H., Jansen, T. J. P., Laverman, G. D., Urgert, T., Geessink-Mennink, J., Mulder, A. H. L., Out, M., Veldman, R. G., Onvlee, A. J., et al. (2024) · The Lancet Digital Health · doi:10.1016/s2589-7500(24)00002-5 · Cited by 45
Automated insulin delivery in older adults with type 1 diabetes
Kudva, Y. C., Henderson, R. J., Kanapka, L. G., Weinstock, R. S., Rickels, M. R., Pratley, R. E., Chaytor, N., Janess, K., Desjardins, D., Pattan, V., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2400200 · Cited by 45
Self-citationKovatchev, B. P., Colmegna, P. H., Pavan, J., C., J. L. D., Villa-Tamayo, M. F., Koravi, C. L. K., Santini, G., Alix, C., Stumpf, M. M., & Brown, S. A. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01679-y · Cited by 50
Self-citationPrahalad, P., Ebekozien, O. A., Alonso, G. T., Clements, M. A., Corathers, S. D., DeSalvo, D. J., Desimone, M. E., Lee, J. M., Lorincz, I. S., McDonough, R., et al. (2021) · Clinical Diabetes · doi:10.2337/cd21-0026 · Cited by 45
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Self-citationNutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications
March, C. A., BECKER, D. J., & Libman, I. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622901 · Cited by 50
Automated insulin delivery systems: from early research to routine care of type 1 diabetes
Renard, É. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01929-5 · Cited by 50
Toffanin, C., Kozak, M., Šumnı́k, Z., Cobelli, C., & Petruželková, L. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0375 · Cited by 46
Petruželková, L., Jiranova, P., Šoupal, J., Kozak, M., Plachý, L., Neuman, V., Průhová, Š., Obermannová, B., Koloušková, S., & Šumnı́k, Z. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13190 · Cited by 43
Aiello, E. M., Deshpande, S., Özaslan, B., Wolkowicz, K. L., Dassau, E., Pinsker, J. E., & Doyle, F. J. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100312 · Cited by 44
Self-citationClosed-loop insulin delivery: update on the state of the field and emerging technologies
Ware, J., & Hovorka, R. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2142556 · Cited by 47
Zaharieva, D. P., Morrison, D., Paldus, B., Lal, R., Buckingham, B. A., & O'Neal, D. N. (2023) · Diabetes Spectrum · doi:10.2337/dsi22-0018 · Cited by 43
Self-citationCriego, A. B., Carlson, A. L., Brown, S. A., Forlenza, G. P., Bode, B. W., Levy, C. J., Hansen, D. W., Hirsch, I. B., Bergenstal, R. M., Sherr, J. L., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0364 · Cited by 43
Self-citationCobry, E. C., Berget, C., Messer, L. H., & Forlenza, G. P. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0055 · Cited by 43
Self-citationTraining and Support for Hybrid Closed-Loop Therapy
Boughton, C. K., Hartnell, S., Allen, J. M., Fuchs, J., & Hovorka, R. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820955168 · Cited by 44
Borel, A.-L., Lablanche, S., Waterlot, C., Joffray, E., Barra, C., Arnol, N., Amougay, H., & Benhamou, P.-Y. (2024) · Diabetes Care · doi:10.2337/dc24-0623 · Cited by 43
Aktürk, H. K., Snell‐Bergeon, J. K., & Shah, V. N. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0162 · Cited by 42
Haidar, A., Yale, J., Lovblom, L. E., Cardinez, N., Orszag, A., Falappa, C. M., Gouchie‐Provencher, N., Tsoukas, M. A., Fathi, A. E., René, J., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14335 · Cited by 44
Montaser, E., Fabris, C., & Kovatchev, B. P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0104 · Cited by 44
Self-citationAmerican Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-ad08c · Cited by 41
Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 55
Asarani, N. A. M., Reynolds, A. N., Elbalshy, M. M., Burnside, M. J., de Bock, M. I., Lewis, D. M., & Wheeler, B. J. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01623-4 · Cited by 44
Haidar, A., Lovblom, L. E., Cardinez, N., Gouchie‐Provencher, N., Orszag, A., Tsoukas, M. A., Falappa, C. M., Jafar, A., Ghanbari, M., Eldelekli, D., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01805-3 · Cited by 45
Bionic Pancreas Research Group, Beck, R. W., Russell, S. J., Damiano, E. R., El-Khatib, F. H., Ruedy, K. J., Balliro, C., Li, Z., & Calhoun, P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0167 · Cited by 40
Self-citationNagaraj, P., Deepalakshmi, P., & Ijaz, M. F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85751-2.00010-4 · Cited by 40
Lin, Y. K., Richardson, C. R., Dobrin, I., DeJonckheere, M. J., Mizokami‐Stout, K., Fetters, M. D., Aikens, J. E., Fisher, S. J., Ye, W., & Pop‐Busui, R. (2022) · Diabetes Care · doi:10.2337/dc21-1285 · Cited by 40
van Veldhuisen, C. L., Latenstein, A. E. J., Blauw, H., Vlaskamp, L. B., Klaassen, M., Lips, D. J., Bonsing, B. A., van der Harst, E., Stommel, M. W. J., Bruno, M. J., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.3702 · Cited by 44
Polsky, S., Buschur, E., Dungan, K., Garcetti, R., Nease, E., Malecha, E., Bartholomew, A., Johnson, C., Pyle, L., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0012 · Cited by 39
Metadata
- Authors
- Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., Dassau, E., Doyle, F. J., Anderson, S. M., Church, M. M., Dadlani, V., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Kollman, C., & Beck, R. W.
- Affiliations
- Sansum Diabetes Research Institute (US)
- Mayo Clinic (US)
- Joslin Diabetes Center (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-31
- Volume
- 381
- Issue
- 18
- Pages
- 1707-1717
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7076915
- OpenAlex
- W2981310284
- Semantic Scholar
- a8aee7f3c717498afd65ea39bd87dd1c1ea5d693
- Cited by
- 1,030
- References
- 17
- Citations by year
- 2026: 128 · 2025: 134 · 2024: 140 · 2023: 180 · 2022: 158 · 2021: 156 · 2020: 125 · 2019: 8
- FWCI
- 90.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4 DK108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, sensor-augmented pump, continuous glucose monitoring, glycemic control, HbA1c, hypoglycemia, hyperglycemia, insulin pump therapy, glycemic variability, HbA1c reduction, hypoglycemia risk reduction, HbA1c thresholds, hypoglycemia risk
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Pancreas, Artificial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
